NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B (HBV) and hepatitis D (HDV) patients, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted six abstracts for presentation at the EASL 2015 annual meeting to be held April 22-26, 2015 in Vienna, Austria.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
